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BACKGROUND
Neonatal hypoglycemia is common and can cause neurologic impairment, but 
evidence supporting thresholds for intervention is limited.
METHODS
We performed a prospective cohort study involving 528 neonates with a gesta-
tional age of at least 35 weeks who were considered to be at risk for hypoglycemia; 
all were treated to maintain a blood glucose concentration of at least 47 mg per 
deciliter (2.6 mmol per liter). We intermittently measured blood glucose for up to 
7 days. We continuously monitored interstitial glucose concentrations, which were 
masked to clinical staff. Assessment at 2 years included Bayley Scales of Infant 
Development III and tests of executive and visual function.
RESULTS
Of 614 children, 528 were eligible, and 404 (77% of eligible children) were as-
sessed; 216 children (53%) had neonatal hypoglycemia (blood glucose concentra-
tion, <47 mg per deciliter). Hypoglycemia, when treated to maintain a blood glu-
cose concentration of at least 47 mg per deciliter, was not associated with an 
increased risk of the primary outcomes of neurosensory impairment (risk ratio, 
0.95; 95% confidence interval [CI], 0.75 to 1.20; P = 0.67) and processing difficulty, 
defined as an executive-function score or motion coherence threshold that was 
more than 1.5 SD from the mean (risk ratio, 0.92; 95% CI, 0.56 to 1.51; P = 0.74). 
Risks were not increased among children with unrecognized hypoglycemia (a low 
interstitial glucose concentration only). The lowest blood glucose concentration, 
number of hypoglycemic episodes and events, and negative interstitial increment 
(area above the interstitial glucose concentration curve and below 47 mg per deci-
liter) also did not predict the outcome.
CONCLUSIONS
In this cohort, neonatal hypoglycemia was not associated with an adverse neuro-
logic outcome when treatment was provided to maintain a blood glucose concen-
tration of at least 47 mg per deciliter. (Funded by the Eunice Kennedy Shriver 
National Institute of Child Health and Human Development and others.)
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Neonatal hypoglycemia is a com-mon and readily treatable risk factor for neurologic impairment in children. Al-
though associations between prolonged symp-
tomatic neonatal hypoglycemia and brain injury 
are well established,1 the effect of milder hypo-
glycemia on neurologic development is uncer-
tain.2 Consequently, large numbers of newborns 
are screened and treated for low blood glucose 
concentrations, which involves heel-stick blood 
tests, substantial costs, and the possibility of 
iatrogenic harm.
Under current guidelines,3 up to 30% of neo-
nates are considered to be at risk for hypoglyce-
mia, 15% receive a diagnosis of hypoglycemia, and 
approximately 10% require admission to a neo-
natal intensive care unit,4 costing an estimated 
$2.1 billion annually in the United States alone.5 
Associated formula feeding and possible separa-
tion of mother and baby reduce breast-feeding 
rates,6 with potentially adverse effects on broad-
er infant health and development. In addition, 
pain-induced stress in neonates, such as repeat-
ed heel sticks, may itself impair brain develop-
ment.7 Thus, to determine appropriate glycemic 
thresholds for treatment, there have been repeated 
calls for studies of the effect of neonatal hypo-
glycemia on long-term development.2,8
We report the results of the Children with 
Hypoglycaemia and Their Later Development 
(CHYLD) study, a large prospective cohort study 
of term and late-preterm neonates born at risk 
for hypoglycemia. The study investigated the rela-
tion between the duration, frequency, and severity 
of low glucose concentrations in the neonatal 
period and neuropsychological development at 
2 years.
Me thods
Study Design and Participants
Eligible infants were those at risk for neonatal 
hypoglycemia primarily on the basis of maternal 
diabetes, preterm birth (gestational age of <37 
weeks), or a birth weight that was low (<10th 
percentile or <2500 g) or high (>90th percentile 
or >4500 g).6 Infants were enrolled before or 
shortly after birth in one of two parallel studies: 
the Babies and Blood Sugar’s Influence on EEG 
Study (BABIES) (102 infants) and the Sugar Ba-
bies study (514 infants), conducted from 2006 to 
2010 at Waikato Hospital, in Hamilton, New Zea-
land, a regional public hospital with 5500 births 
annually.6,9 Infants with serious congenital mal-
formations or terminal conditions were excluded. 
Cohort characteristics, glycemic management, and 
neonatal outcomes have been reported previ-
ously.6,9,10 Infants underwent regular measure-
ment of blood glucose concentrations by means 
of the glucose oxidase method (ABL800 FLEX, 
Radiometer) for 24 to 48 hours or until there were 
no ongoing clinical concerns. Masked continu-
ous interstitial glucose monitoring (CGMS Gold, 
Medtronic MiniMed) was performed as previously 
described.11,12 Hypoglycemia, defined as a blood 
glucose concentration of less than 47 mg per 
deciliter (2.6 mmol per liter), was treated with any 
combination of additional feeding, buccal dex-
trose gel, and intravenous dextrose to maintain a 
blood glucose concentration of at least 47 mg 
per deciliter. Approximately one third of the in-
fants (237) were enrolled in a randomized, pla-
cebo-controlled trial of buccal dextrose gel.6
Both neonatal studies and the follow-up study 
were approved by the regional ethics committee. 
Written informed consent was obtained from a 
parent or guardian of each infant at study entry 
and at follow-up.
Assessment at 2 Years
At 2 years of corrected age, children born at a 
gestational age of at least 35 weeks underwent 
neurologic examination, tests of executive func-
tion, assessment with the use of the Bayley Scales 
of Infant Development III (BSID-III, a norm-ref-
erenced scale in which composite scores are as-
sessed according to the scale mean [±SD] of 
100±15, and lower scores indicate greater im-
pairment),13 vision screening (for details, see the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org), and global motion 
perception testing (assessment of dorsal-visual-
pathway function, measured as optokinetic re-
flex responses to random-dot kinematograms of 
varying coherence).14 Caregivers completed ques-
tionnaires about the home environment, the 
child’s health, and — with the use of the Behav-
ior Rating Inventory of Executive Function–pre-
school version (BRIEF-P) — the child’s executive 
function.15 All children underwent neonatal au-
diologic screening, with targeted audiologic fol-
low-up when indicated.
Executive-function tests comprised four tasks 
that assess inhibitory control (snack delay and 
A Quick Take 
is available at 
NEJM.org
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shape stroop),16 capacity for reverse categoriza-
tion (ducks and buckets),17 and attentional flex-
ibility (multisearch, multilocation task).18 Scores 
(ranging from 0 to 6 points per task, with higher 
scores indicating better function) were summed 
to obtain an executive-function score of up to 24 
points.
Prespecified primary outcomes were neuro-
sensory impairment and processing difficulty. 
Neurosensory impairment was defined as any of 
the following findings: developmental delay 
(BSID-III cognitive or language composite score 
of <85), motor impairment (BSID-III motor com-
posite score of <85), cerebral palsy,19 hearing im-
pairment (requiring hearing aids), or blindness 
(≥1.4 logMAR [log10 of the minimal angle of reso-
lution] in both eyes). Processing difficulty was de-
fined as either a motion coherence threshold or an 
executive-function score that was more than 1.5 SD 
from the mean, indicating performance in the 
worst 7% of the cohort. Secondary outcomes 
included individual components of the primary 
outcomes, BSID-III scores for social and emo-
tional function and adaptive behavior, vision-
impairment and refractive-error scores, T scores 
on the BRIEF-P, and seizures.
Statistical Analysis
Analysis was performed with SAS software, ver-
sion 9.4 (SAS Institute). Primary analyses com-
pared primary and secondary outcomes between 
children with and those without hypoglycemic 
episodes in the first week after birth (any episode, 
≥3 episodes, episodes on ≥3 days, and any severe 
episode), with the use of generalized linear mod-
els adjusted for prespecified potential confound-
ers (socioeconomic decile,20 sex, and primary risk 
factor for neonatal hypoglycemia). A hypoglyce-
mic episode was defined as a blood glucose con-
centration of less than 47 mg per deciliter on a 
single measurement or consecutive measure-
ments, with a severe episode defined as a blood 
glucose concentration of less than 36 mg per 
deciliter (2.0 mmol per liter). Interstitial episodes 
were defined as periods of interstitial glucose 
concentrations that were below those thresholds 
for at least 10 minutes. Results are presented as 
risk ratios and mean differences with 95% con-
fidence intervals. A two-tailed alpha level of less 
than 0.05 was considered to indicate statistical 
significance, with no adjustment for multiple com-
parisons. Sample size was limited by the size of 
the inception cohorts, but we estimated that this 
study would have 80% power to detect between-
group differences in BSID-III scores of 5 points 
or more.
Secondary analyses related continuous mea-
sures of hypoglycemic exposure to primary 
outcomes, with the use of receiver-operating-
characteristic (ROC) curves. To explore the 
predictive value of different glycemic thresh-
olds for adverse neurodevelopmental outcomes, 
the negative interstitial increment was used, 
calculated as the area above the interstitial 
glucose concentration curve and below a given 
Figure 1. Cohort of Children Followed up at 2 Years.
BABIES denotes Babies and Blood Sugar’s Influence on EEG Study,  
BRIEF-P Behavior Rating Inventory of Executive Function–preschool  
version, and BSID-III Bayley Scales of Infant Development III. Pediatric  
assessment included history taking and physical examination (including 
neurologic examination) by a pediatrician.
528 Were eligible for 2-yr follow-up
(86% of neonatal cohort)
614 Infants were recruited for two neonatal 
studies (BABIES and Sugar Babies)
86 Were not eligible
2 Died
65 Were >2 yr old
19 Had gestational age of <35 wk 
405 Were recruited
(77% of eligible children; 66% of neonatal cohort)
123 Were not recruited
79 Declined to participate
11 Were lost to follow-up
33 Moved overseas
404 Completed follow-up
(77% of eligible children; 66% of neonatal cohort)
1 Died
402 Were included in the BSID-III analysis
393 Were included in the executive-function
analysis
399 Were included in the BRIEF-P analysis
401 Were included in the vision assessment
396 Were included in the pediatric assessment
404 Were included in the neonatal audiologic
assessment
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Characteristic Participants Nonparticipants
Total
Neonatal 
Hypoglycemia
No Neonatal 
Hypoglycemia
Maternal
No. of women 376 201 175 115
Age — yr 29.9±6.3 29.9±6.1 30.0±6.5 29.0±7.0
Body-mass index in early pregnancy† 29.3±7.6 29.1±7.4 29.5±7.8 27.2±6.0‡
Diabetes during pregnancy — no. (%)
Gestational 129 (34)   58 (29)§ 71 (41) 40 (35)
Pregestational 28 (7)  20 (10) 8 (5) 4 (3)
Controlled by diet  36 (10) 16 (8) 20 (11) 11 (10)
Treated with oral hypoglycemic agent 22 (6)  6 (3) 16 (9) 3 (3)
Treated with insulin  86 (23)  49 (24) 37 (21) 23 (20)
Neonatal
No. of infants 404 216 188 124
Female sex — no. (%) 192 (48)  116 (54)¶ 76 (40) 55 (44)
Twin — no. (%)  51 (13)  32 (15) 19 (10) 17 (14)
Ethnic group — no. (%)‖
Maori 115 (28)  60 (28) 55 (29) 42 (34)
Pacific Islander 14 (3)  7 (3) 7 (4) 0
Other  69 (17)  31 (14) 38 (20) 31 (25)
New Zealand European 206 (51) 118 (55) 88 (47) 51 (41)
Socioeconomic decile 4.5±2.7 4.5±2.7 4.5±2.7 4.3±2.5
Gestational age — wk 37.8±1.7 37.7±1.6 37.8±1.7 37.8±1.8
Birth weight — g 3134±844 3089±811 3187±879 3026±883
Birth weight z score 0.19±1.68 0.13±1.70 0.25±1.65 −0.05±1.71
Admitted to NICU — no. (%) 156 (39)  101 (47)¶ 55 (29) 50 (40)
Primary risk factor for neonatal hypoglycemia — no. (%)
Maternal diabetes 161 (40)  80 (37) 81 (43) 44 (35)
Late preterm: gestational age of 35 or 36 wk 129 (32)  71 (33) 58 (31) 43 (35)
Small: <10th percentile or <2.5 kg  60 (15)  39 (18) 21 (11) 18 (15)
Large: >90th percentile or >4.5 kg  42 (10) 17 (8) 25 (13) 12 (10)
Other** 12 (3)  9 (4) 3 (2) 7 (6)
Blood glucose monitoring
Median age at first sample (IQR) — hr 1.5 (1.2–2.1) 1.5 (1.2–2.0) 1.5 (1.2–2.2) 1.6 (1.2–2.1)
Duration of monitoring — hr 52.8±27.2 58.9 ±27.4¶ 45.7±25.3 53.5±29.4
No. of samples in first week 14.7±5.7 16.3±6.0¶ 11.6±3.5 15.4±4.6
Blood glucose (range) — mg/dl††
<12 hr 59.5±10.8 
(9.0–137.0)
54.1±7.2 
(9.0–127.9)¶
64.9±10.8 
(46.8–136.9)
59.5±10.8 
(12.6–133.3)
12 to <24 hr 64.9±12.6) 
(32.4–154.9)
61.3±10.8 
(32.4–127.9)¶
68.5±12.6 
(46.8–145.9)
66.7±10.8 
(36.0–126.1)‡‡
24 to <48 hr 66.7±10.8 
(16.2–155.0)
63.1±10.8 
(16.2–155.0)¶
70.3±10.8 
(46.8–129.7)
68.5±10.8 
(37.8–111.7)
≥48 hr 75.7±14.4 
(19.8–171.2)
72.1±12.6 
(19.8–171.2)¶
79.3±14.4 
(48.6–127.9)
77.5±14.4 
(34.2–176.6)
Table 1. Maternal and Neonatal Characteristics of the Study Participants and Nonparticipants.*
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threshold. Repeated-measures mixed models 
explored trend over time. Logistic regression 
was used to estimate the likelihood of the pri-
mary outcomes according to quantile of con-
tinuous glycemic variables.
R esult s
Study Cohort
The cohort comprised 614 infants (2 infants 
participated in both neonatal studies) (Fig. 1). 
Characteristic Participants Nonparticipants
Total
Neonatal 
Hypoglycemia
No Neonatal 
Hypoglycemia
Hypoglycemia — no. (%)
≥1 Episode 216 (53)  216 (100)¶ 0 61 (49)
≥3 Episodes 34 (8)  34 (16)¶ 0 10 (8)
Episodes on ≥3 days in first week 12 (3) 12 (6)¶ 0 1 (1)
Severe hypoglycemia — no. (%)
≥1 Episode  64 (16)  64 (30)¶ 0 18 (15)
≥3 Episodes  3 (1)  3 (1)¶ 0 0
Episodes on ≥3 days in first week   1 (<1)   1 (<1)¶ 0 0
Interstitial glucose monitoring
No. of infants (%) 305 (75) 164 (76) 141 (75) 80 (65)
Median age when recording commenced (IQR) 
— hr
4.0 (2.5–6.2) 3.2 (2.3–5.3)¶ 4.9 (3.2–6.6) 4.4 (2.4–7.3)
Duration of monitoring — hr 43.7±21.4 48.9±22.4¶ 37.7±18.5 43.8±22.4
≥1 Episode with glucose at <47 mg/dl — no. (%) 163 (53) 130 (79)¶ 33 (23) 36 (45)
≥1 Episode with glucose at <36 mg/dl — no. (%)  43 (14)  39 (24)¶ 4 (3) 8 (10)
Median time with glucose at <47 mg/dl (IQR) — 
min
In first 48 hr 15 (0–145) 103 (15–273)¶ 0 (0–0) 0 (0–90)
In first week 20 (0–145) 105 (20–303)¶ 0 (0–0) 0 (0–103)
Neonatal dextrose treatment — no. (%)
Oral gel only 101 (25) 101 (47) 0 35 (28)
Intravenous only 22 (5) 12 (6) 10 (5) 10 (8)
Oral gel and intravenous 21 (5)  21 (10) 0 1 (1)
*  Plus–minus values are means ±SD unless otherwise specified. A hypoglycemic episode was defined as a blood glucose concentration of 
less than 47 mg per deciliter (2.6 mmol per liter) on a single measurement or consecutive measurements; an episode of severe hypogly-
cemia was defined as a blood glucose concentration of less than 36 mg per deciliter (2.0 mmol per liter). An interstitial episode or a se-
vere interstitial episode was defined as an interstitial glucose concentration below the respective threshold for least 10 minutes. To con-
vert values for glucose to millimoles per liter, multiply by 0.05551. See the Supplementary Appendix for data on maternal gravidity and 
parity, weight gain during pregnancy, smoking status, alcohol use during pregnancy, maternal education, mode of birth, 5-minute Apgar 
score, and infant feeding in the first week. IQR denotes interquartile range, and NICU neonatal intensive care unit.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters. Data on maternal body-mass index were 
missing for 4 participants and 1 nonparticipant.
‡  P<0.01 for the comparison with participants.
§  P<0.05 for the comparison with children who did not have neonatal hypoglycemia.
¶  P<0.01 for the comparison with children who did not have neonatal hypoglycemia.
‖  Information on ethnic group was reported by the parent or guardian. Children could be assigned to more than one ethnic group; in such 
cases, ethnic groups were prioritized in the following order: Maori, Pacific Islander, Other, and New Zealand European. P<0.01 for the 
comparison of nonparticipants with participants.
**  Other risk factors included sepsis, hemolytic disease of the newborn, respiratory distress, congenital heart disease, and poor feeding.
††  The mean was calculated from the mean blood glucose value for each infant; the range is for all blood glucose concentrations.
‡‡  P<0.05 for the comparison with participants.
Table 1. (Continued.)
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Because follow-up started after some children 
were older than 2 years of age and those born 
before 35 weeks’ gestation were excluded, 528 
children were eligible, of whom 404 (77% of eli-
gible infants) were assessed at a mean (±SD) 
corrected age of 24.3±1.9 months. Eligible chil-
dren who did not participate in the study were 
more likely to be of Maori or other non-Europe-
an ethnic origin, and their mothers had a slightly 
lower body-mass index but were similar with re-
spect to other baseline variables (Table 1).
Neonatal Hypoglycemia
Although neonatal hypoglycemia was common 
(observed in 216 children [53%]), regular mea-
surement of blood glucose concentrations and 
No./Total No. (%) No./Total No. (%)
Less Impairment More Impairment Less Difficulty More Difficulty
Less Impairment More Impairment Less Difficulty More Difficulty
0.5 1.0 1.5 2.0 2.50.0 0.5 1.0 1.5 0.02.0
Adjusted Risk Ratio (95% CI)
of Neurosensory Impairment
No Hypoglycemia (reference)
Hypoglycemia
Hypoglycemia ≥3 Episodes
Hypoglycemia ≥3 Days
 Severe Hypoglycemia
73/188 (39)
79/216 (37)
9/34 (26)
1/12 (8)
28/64 (44)
27/171 (16)
27/198 (14)
2/31 (6)
0/11
10/53 (19)
Adjusted Risk Ratio (95% CI)
of Processing Difficulty
Adjusted Risk Ratio (95% CI)
of Neurosensory Impairment
Adjusted Risk Ratio (95% CI)
of Processing Difficulty
B
A
1.0 10.00.1 1.0 0.110.0
Percent of time outside central band
 during the first 48 hr
(Q1–5: 0, 33, 50, 60, 73%)
Mean during the first 48 hr
(Q1–5: 40, 56, 59, 65, 70 mg/dl)
Percent of time outside central band
 during the first 48 hr
(Q1–5: 0, 23, 41, 57, 74%)
Mean during the first 48 hr
(Q1–5: 47, 58, 63, 67, 76 mg/dl)
Maximum during the first 12 hr
(Q1–5: 45, 63, 70, 77, 88 mg/dl)
0.004
0.04
0.09
0.04
0.03
0.62
0.79
0.93
0.38
0.92
P ValueP Value
369
369
274
274
257
No.
404
404
302
302
283
No.
Blood Glucose
Interstitial Glucose
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early treatment meant that recurrent hypoglyce-
mia was infrequent (Table 1). Nevertheless, con-
tinuous interstitial glucose monitoring showed 
that nearly one quarter of the infants had low 
glucose concentrations that were not detected by 
intermittent blood glucose monitoring. Even with 
treatment, many infants had prolonged periods 
of low interstitial glucose concentrations. Thus, 
25% of those treated for neonatal hypoglycemia 
had at least 5 hours of low interstitial glucose 
concentrations during the first week (Table 1).
Neurodevelopmental Impairment at 2 Years
The risk of neurosensory impairment or process-
ing difficulty was not higher among children with 
neonatal hypoglycemia (when treated to maintain 
a blood glucose concentration of at least 47 mg 
per deciliter) than among those without neona-
tal hypoglycemia (risk ratio for neurosensory 
impairment, 0.95; 95% confidence interval [CI], 
0.75 to 1.20; P = 0.67; 404 children included in 
the analysis; and risk ratio for processing diffi-
culty, 0.92; 95% CI, 0.56 to 1.51; P = 0.74; 369 
children included in the analysis), even among 
children with multiple hypoglycemic episodes, 
episodes on multiple days, or severe episodes 
(Fig. 2A). Children with neonatal hypoglycemia 
had slightly better BSID-III scores for social and 
emotional adaptation than did children without 
neonatal hypoglycemia (mean difference in scores, 
3.5 points; 95% CI, 0.4 to 6.5; P = 0.02) (Table 2), 
but other secondary outcomes were similar in the 
two study groups (Table S2 in the Supplemen-
tary Appendix). Furthermore, children with un-
recognized and therefore untreated low glucose 
concentrations (detected only on continuous in-
terstitial glucose monitoring) also had no in-
creased risk of abnormal neurodevelopment as 
compared with those with no evidence of low 
blood glucose concentrations (neurosensory im-
pairment in 14 of 33 children vs. 45 of 108; risk 
ratio, 1.01; 95% CI, 0.66 to 1.54; P = 0.98; and 
processing difficulty in 5 of 29 children vs. 17 of 
99; risk ratio, 0.92; 95% CI, 0.38 to 2.23; P = 0.86).
As continuous predictors, the lowest blood 
glucose concentration, number of hypoglycemic 
episodes (including severe episodes), and number 
of combined hypoglycemic events (blood and in-
terstitial episodes) in the first week did not dis-
criminate between children with and those with-
out later neurodevelopmental impairment (Fig. 
S1 in the Supplementary Appendix). Similarly, at 
thresholds below 47 mg per deciliter, the nega-
tive interstitial increment was not predictive of 
neurosensory impairment. There was some evi-
dence of a discriminative association at thresh-
olds above 54 mg per deciliter (3.0 mmol per liter) 
(Fig. S1 in the Supplementary Appendix) but in 
the reverse direction, suggesting that neurosen-
sory impairment was associated with higher neo-
natal glucose concentrations, even though clinical 
hyperglycemia was uncommon (3 infants had a 
blood glucose concentration >144 mg per decili-
ter [8.0 mmol per liter]). Furthermore, children 
with neurosensory impairment at 2 years had 
slightly higher interstitial glucose concentrations 
throughout the first 48 hours than did those 
with normal neurosensory function (mean dif-
ference, 2.9 mg per deciliter [0.2 mmol per liter]; 
95% CI, 0.5 to 5.2 mg per deciliter [0.0 to 0.3 mmol 
per liter]; P = 0.02; 302 children included in the 
analysis) (Fig. 3A).
Given the potential for a U-shaped relation 
between neonatal glucose concentrations and 
neurodevelopmental impairment, we calculated 
the time outside a central band,21 defined as the 
proportion of blood or interstitial glucose mea-
surements that were less than 54 mg per decili-
Figure 2 (facing page). Effect of Hypoglycemia on the 
Primary Outcome and Relation between Continuous 
Glycemic Exposure and the Primary Outcome.
Panel A shows the effect of hypoglycemia on the risk 
of the primary outcome. A hypoglycemic episode was 
defined as a blood glucose concentration of less than 
47 mg per deciliter (2.6 mmol per liter) on a single 
measurement or consecutive measurements; severe 
hypoglycemia was defined as a blood glucose concen-
tration of less than 36 mg per deciliter (2.0 mmol per 
liter). Results were adjusted for socioeconomic de-
cile,20 sex, and primary risk factor for neonatal hypo-
glycemia. Panel B shows the relationship between 
continuous glycemic exposure and the primary out-
come. Logistic regression was used to compare the 
risk of an adverse outcome according to the quintile of 
the continuous glycemic variable in the first 48 hours. 
Results were adjusted for socioeconomic decile, sex, 
and primary risk factor for neonatal hypoglycemia. Di-
amonds denote quintile 1, upward-pointing triangles 
quintile 2, circles quintile 3 (reference), squares quin-
tile 4, and downward-pointing triangles quintile 5. Val-
ues for quintiles 1 through 5 (Q1–5) represent the 
lowest value for each quintile. The central band was 
defined as a blood glucose or an interstitial glucose 
concentration of 54 to 72 mg per deciliter. To convert 
the values for glucose to millimoles per liter, multiply 
by 0.05551.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF WATERLOO on March 14, 2017. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 373;16 nejm.org October 15, 20151514
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
ter or greater than 72 mg per deciliter (4.0 mmol 
per liter) during the first 48 hours — the thresh-
olds that approximated the lower and upper 
quartiles for all blood glucose concentrations 
during this period. Infants in the highest quin-
tiles of time outside this central band were more 
likely than those in the middle (reference) quin-
tile to have neurosensory impairment; if the pro-
portion of blood glucose values outside the band 
was above the median, the risk ratio for neuro-
sensory impairment was 1.40 (95% CI, 1.09 to 
1.79; P = 0.008; 404 children included in the 
analysis) (Fig. 2B). There was no association be-
tween time outside the central band and pro-
cessing difficulty. Greater time outside the cen-
tral band was associated with an increased risk 
of cognitive delay but not language or motor 
delay. If the proportion of blood glucose concen-
trations outside the band was above the median, 
the risk ratio for cognitive delay was 1.57 (95% 
CI, 1.10 to 2.23; P = 0.01; 402 children included 
in the analysis), the risk ratio for language delay 
was 1.40 (95% CI, 0.97 to 2.01; P = 0.07; 401 
children included in the analysis), and the risk 
ratio for motor delay was 1.64 (95% CI, 0.84 to 
3.19; P = 0.14; 401 children included in the 
analysis). Neurosensory impairment was also 
related to the maximum interstitial glucose con-
centration in the first 12 hours (Fig. 2B). Al-
though the time outside the central band was 
greater for infants with hypoglycemia than for 
those without hypoglycemia (mean difference in 
the proportion of blood glucose concentrations 
outside the central band, 0.11; 95% CI, 0.07 to 
0.16; P = 0.001), the association between time 
outside the central band and neurosensory im-
pairment was not influenced by neonatal hypo-
glycemia (P = 0.54 for interaction).
Outcome Neonatal Hypoglycemia No Neonatal Hypoglycemia
Adjusted Difference 
in Means 
or Risk Ratio (95% CI) P Value
Result
No. 
Assessed Result
No. 
Assessed
BSID-III composite scores†
Cognitive 93.8±10.0 215 93.1±10.5 187 0.6 (−1.3 to 2.6) 0.55
Language 95.5±13.1 215 93.8±15.4 187 1.4 (−1.3 to 4.1) 0.30
Motor 98.6±9.4 215 98.7±9.7 187 −0.2 (−2.1 to 1.6) 0.81
Social–emotional 104.3±15.3 207 100.5±14.7 175 3.5 (0.4 to 6.5) 0.02
Adaptive behavior 99.6±14.1 209 98.4±15.8 177 0.3 (−2.7 to 3.3) 0.84
Developmental delay — no. (%)‡ 70 (33) 215 68 (36) 187 0.90 (0.70 to 1.17) 0.44
Executive-function score 10.6±4.4 207 10.3±4.1 177 0.3 (−0.5 to 1.1) 0.49
BRIEF-P global T score >65 — no. (%)§ 46 (21) 214 44 (24) 184 0.84 (0.59 to 1.20) 0.34
Motion coherence threshold — %¶ 41.5±14.2 204 43.2±13.4 175 −1.7 (−4.5 to 1.1) 0.24
Cerebral palsy — no. (%) 2 (1) 216 2 (1) 185 0.81 (0.11 to 5.99) 0.83
Seizures, any — no. (%) 10 (5) 212 11 (6) 184 0.71 (0.31 to 1.64) 0.42
*  Plus–minus values are means ±SD unless otherwise specified. Between-group differences (children with neonatal hypoglycemia vs. children 
without neonatal hypoglycemia) are expressed as differences between means for Bayley Scales of Infant Development III (BSID-III) scores, 
executive-function score, and motion coherence threshold and as risk ratios for developmental delay, Behavior Rating Inventory of Executive 
Function–preschool version (BRIEF-P) global T score higher than 65, cerebral palsy, and seizures, with adjustment for socioeconomic decile, 
sex, and primary risk factor for neonatal hypoglycemia. See the Supplementary Appendix for the following additional outcomes: T scores on the 
BRIEF-P, executive dysfunction, visual-processing difficulty, scores for vision impairment and refractive error, hearing impairment, and 
blindness.
†  BSID-III scores have a standardized mean (±SD) of 100±15, with higher scores indicating better development.
‡  Developmental delay was defined as a BSID-III cognitive or language score of less than 85.
§  T scores on the BRIEF-P have a standardized mean of 50±10, with higher scores indicating worse functioning. A score higher than 65 is con-
sidered to be indicative of a clinically significant problem with executive function.
¶  Motion coherence threshold is a measurement of dorsal-visual-pathway function, determined from optokinetic reflex responses to random-
dot kinematograms of varying coherence. Higher thresholds indicate worse visual processing ability.
Table 2. Secondary Outcomes at 2 Years in Children with and Those without Neonatal Hypoglycemia.*
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Among children who had neonatal hypogly-
cemia, those with subsequent neurosensory im-
pairment had a steeper initial rise in interstitial 
glucose concentrations and higher concentrations 
for 12 hours after birth than did the children 
without neurosensory impairment (mean differ-
ence, 4.9 mg per deciliter [0.3 mmol per liter]; 
95% CI, 1.4 to 8.3 mg per deciliter [0.1 to 0.5 mmol 
per liter]; P = 0.007; 162 children included in the 
analysis) (Fig. 3B). This higher interstitial glu-
cose curve was seen only among infants treated 
with dextrose, whether it was administered orally, 
intravenously, or both (mean difference during 
the first 12 hours after birth, 9.2 mg per decili-
ter [0.5 mmol per liter]; 95% CI, 4.3 to 13.9 mg 
per deciliter [0.2 to 0.8 mmol per liter]; P<0.001) 
(Fig. 3C and 3D) and was temporally related to 
the first hypoglycemic episode (Fig. 3E). Further-
more, the risk of neurosensory impairment among 
infants treated with dextrose was related to the 
maximum interstitial glucose concentration with-
in 12 hours after the first episode; if the maxi-
mum interstitial glucose concentration was above 
the median, the risk ratio was 1.77 (95% CI, 1.01 
to 3.11; P = 0.047; 100 children included in the 
analysis). Dextrose treatment was associated with 
higher interstitial glucose concentrations for ap-
proximately 36 hours after the first hypoglyce-
mic episode, as compared with no dextrose treat-
ment (Fig. S2 in the Supplementary Appendix). 
Infants receiving intravenous dextrose had high-
er maximum interstitial glucose concentrations 
during the first 12 hours after the first hypogly-
cemic episode than did those treated with dex-
trose gel alone (mean difference, 18.2 mg per 
deciliter [1.0 mmol per liter]; 95% CI, 12.8 to 
25.4 mg per deciliter [0.7 to 1.4 mmol per liter]; 
P<0.001), though the risk of neurosensory im-
pairment in these subgroups was similar (37 of 
101 children vs. 14 of 33; risk ratio, 1.08; 95% 
CI, 0.71 to 1.67; P = 0.71).
Discussion
After reports of altered somatosensory evoked 
potentials and an increased incidence of devel-
opmental delay in infants with glucose concen-
trations of less than 47 mg per deciliter,22,23 a 
glucose concentration of 47 mg per deciliter 
became a well-accepted glycemic threshold for 
treatment in newborns,3 despite the lack of evi-
dence that intervention at this threshold is safe 
or effective.8 The use of this threshold in new-
borns is perhaps surprising, given that blood 
glucose concentrations below 60 mg per deciliter 
(3.3 mmol per liter) are considered low in chil-
dren and adults.21 In this large prospective study 
of at-risk term and late-preterm infants, we found 
that with a treatment threshold of 47 mg of glu-
cose per deciliter, neonatal hypoglycemia was not 
associated with adverse neurodevelopmental out-
comes at 2 years. Our study suggests that a 
protocol of regular blood glucose monitoring in 
the first 48 hours after birth and intervention 
aimed at maintaining a blood glucose concen-
tration of at least 47 mg per deciliter is effective 
in preventing neuronal injury in at-risk term and 
late-preterm newborns.
It is important to distinguish between thresh-
olds for intervention that can be safely applied to 
all infants and the lowest glucose concentration 
at which clinically significant neuroglycopenia is 
avoided.22 It is unlikely that neuroglycopenia can 
be defined by a single numerical value, since the 
relationships among glycemic exposure, alterna-
tive cerebral fuels, other perinatal stressors, and 
neuronal function are complex and may be highly 
infant-specific. At present, there are no reliable 
tools to assess the neurologic state in relation to 
the blood glucose concentration in infants.9 There-
fore, clinicians need a pragmatic threshold for 
providing treatment that ensures an adequate sup-
ply of metabolic fuels for the developing brain 
during the neonatal transition.
In our study, continuous interstitial glucose 
monitoring showed that episodes of low glucose 
concentrations were common, even in infants 
thought to have normal blood glucose concen-
trations and those receiving treatment for hypo-
glycemia. Although these data could be interpreted 
as evidence that a lower glycemic threshold for 
treatment might be safe, they also highlight the 
need for a considerable margin of safety in set-
ting such a threshold. We were not able to estab-
lish an association between the degree of hypo-
glycemia and neurologic outcomes, most likely 
because treatment was effective and the infants 
were monitored closely, so that recurrent or severe 
hypoglycemia was rare. However, a recent retro-
spective study showed a graded association be-
tween hypoglycemic thresholds of less than 40 mg 
per deciliter (2.2 mmol per liter) and neurodevel-
opmental impairment in late-preterm infants, an 
observation that provides grounds for caution, 
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particularly since the infants were followed for 
longer than 2 years in that study.23 Furthermore, 
whereas a lower threshold may reduce the need 
for intervention, it may not reduce the require-
ment for screening and associated costs, since 
hypoglycemia can occur at any stage in the first 
few days after birth, even in infants with normal 
initial glucose concentrations.4 Therefore, if low-
er intervention and treatment thresholds are to 
be considered, it seems reasonable that they 
should be evaluated in randomized trials.
A strength of our study is the comprehensive 
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neuropsychometric assessment undertaken, in-
cluding advanced testing of executive function, 
vision, and visual processing — skills thought to 
be particularly affected by neonatal hypoglyce-
mia.24,25 Therefore, we are confident that our re-
sults are robust and that we would have detected 
clinically significant effects of hypoglycemia on 
neurocognitive processing. Nevertheless, the pos-
sibility remains that hypoglycemia affects skills 
that do not emerge until later phases of develop-
ment, and repeat assessment at 4.5 years of age 
is ongoing.
Another strength of our study is the use of 
continuous interstitial glucose monitoring, which 
provides recordings every 5 minutes, allowing 
detailed characterization of glucose profiles over 
time. Although continuous interstitial glucose 
monitoring remains an important research tool, 
our study suggests that at a treatment threshold 
of 47 mg of glucose per deciliter, screening by 
means of intermittent blood glucose measure-
ment with the use of a reference method is suf-
ficient. However, this may not be the case at 
lower glucose thresholds.
A surprising finding of our study is the asso-
ciation of neurosensory impairment, especially 
cognitive delay, with higher glucose concentrations 
and less glucose stability, indicated by a larger 
proportion of time outside the central range of 
54 to 72 mg per deciliter in the first 48 hours. 
Hyperglycemia (a blood glucose concentration of 
>180 mg per deciliter [10.0 mmol per liter]) is 
associated with neurodevelopmental impairment 
in very preterm infants,26 but an association has 
not previously been reported in more mature in-
fants, especially at glucose concentrations typi-
cally regarded as being within the normal range. 
Furthermore, the estimated effect sizes in our 
study were relatively large, particularly given the 
brief glycemic exposure, with increases in the 
risk of neurosensory impairment ranging from 
40 to 77%, and even higher for infants in the 
uppermost quintiles.
Of concern is the suggestion in our data that 
rapid correction of hypoglycemia to higher blood 
glucose concentrations may be associated with a 
poorer outcome. This finding, in an exploratory 
analysis, was unexpected and must be interpreted 
with caution, since the study was observational 
and unknown confounders cannot be excluded in 
such studies. Furthermore, the association was 
seen only in tests of general development 
(BSID-III), not in tests of processing ability. 
However, this finding is consistent with evi-
dence from animal models that higher blood 
glucose concentrations during recovery from 
hypoglycemia can worsen neurologic damage, at 
least in part because of increased generation of 
reactive oxygen species.27,28 Similarly, in both 
children29 and adults30 in the intensive care unit, 
the combination of hypoglycemia and highly vari-
able glucose concentrations is strongly associated 
with mortality. Thus, the manner in which hy-
poglycemia is treated and the subsequent stabil-
ity of blood glucose concentrations may be im-
portant in newborns. We are currently undertaking 
a randomized trial (ACTRN12613000322730) to 
assess the long-term effects of different doses 
and frequencies of dextrose gel administration.
In the present cohort study, neonatal hypogly-
cemia was not associated with adverse neuro-
logic outcomes when infants were treated with 
the aim of maintaining a blood glucose concen-
tration of at least 47 mg per deciliter (2.6 mmol 
per liter), even though transient low glucose con-
centrations remained common. The possibility 
that blood glucose concentrations at the high end 
of the normal range or unstable blood glucose 
concentrations and rapid correction of hypogly-
cemia may be harmful requires further investi-
gation.
The views expressed in this article are those of the authors 
and do not necessarily represent the official views of the Eunice 
Kennedy Shriver National Institute of Child Health and Human 
Development or the National Institutes of Health.
Figure 3 (facing page). Results of Interstitial Glucose 
Monitoring in Children with and Those without  
Neurosensory Disability at 2 Years.
Data are means and 95% confidence intervals and 
represent the per-child 0.5-hour average of continuous 
interstitial glucose concentrations. ∆IG denotes the 
mean difference in the first 12 hours or first 48 hours, 
as determined from repeated-measures analysis, and 
IG*t the group–time interaction. Panel A shows data 
for all 302 children who underwent interstitial moni-
toring in the first 48 hours after birth, Panel B shows 
data for the 162 children with neonatal hypoglycemia, 
Panel C shows data for the 104 children with neonatal 
hypoglycemia who were treated with dextrose (buccal 
dextrose gel, intravenous dextrose, or both), Panel D 
shows data for the 58 children with neonatal hypogly-
cemia who were not treated with dextrose, Panel E 
shows interstitial glucose values after the first hypo-
glycemic episode in the 104 children treated with dex-
trose, and Panel F shows data for the 140 children 
without neonatal hypoglycemia.
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